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ABSTRACT
Background and aims: The COVID-19 pandemic and its consequences represent a major challenge to
the mental health and well-being of the general population. Building on previous work on the potential
long-term benefits of psychedelics, we hypothesized that lifetime use of these drugs could be linked to
better mental health indicators in the context of the ongoing pandemic. Methods: Two anonymous
online surveys were conducted between April and June 2020, including questions about lifetime
experience with psychedelics and other psychoactive drugs, and psychometric scales designed to
measure personality traits, anxiety, negative, and positive affect, well-being, and resilience. Principal
component analysis was applied to divide the sample into groups of subjects based on their drug use
reports. Results: Five thousand six hundred eighteen participants (29.15 ± 0.12 years, 71.97% female)
completed both surveys and met the inclusion criteria, with 32.43% of the sample reporting at least one
use of a psychedelic drug. Preliminary analyses showed that certain psychedelics were linked to
improved mental health indicators, while other psychoactive drugs exhibited the opposite behavior.
Lifetime psychedelic use was linked to increased openness and decreased conscientiousness, and to
higher scores of positive affect. The reported number of past psychedelic experiences predicted higher
scores of the secondary personality trait beta factor, which has been interpreted as a measure of
plasticity. No significant associations between lifetime use of psychedelics and indicators of impaired
mental health were observed. Conclusion: We did not find evidence of an association between lifetime
use of psychedelics and poor mental health indicators. Conversely, experience with psychedelic drugs
was linked to increased positive affect and to personality traits that favor resilience and stability in the
light of the ongoing crisis.
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INTRODUCTION
Psychedelic drugs are found in nature in multiple species of plants, fungi and animals
(R€atsch, 2005). The use of certain compounds (i.e., mescaline, psilocybin, N,N-dimethyl-
tryptamine [DMT]) has been documented at least for centuries, mainly in association with
medicinal, religious, and other ceremonial practices (e.g., divination) (Escohotado, 2002). The
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neurotransmitter), which enables their pharmacological ac-
tion as 2A serotonin receptors (5-HT2A) agonists (Nichols,
2016). At the phenomenological, cognitive and behavioral
levels, 5-HT2A agonism is linked to a wide range of effects
that alter the conscious experience of the user, such as
modifications in the perception of the environment and the
self, sedation, stimulation, as well as changes in mood,
prosocial behavior, cognitive flexibility, and creativity,
among others (Jungaberle et al., 2018; Nichols, 2016; Pala-
mar & Acosta, 2020; Preller & Vollwenweider, 2016; Schmid
et al., 2015). These effects attracted the attention of main-
stream science during the 1950s, leading to several in-
vestigations in healthy and clinical populations (Dyck &
Farrell, 2018). However, the widespread availability of psy-
chedelic drugs (mainly LSD) during the 1950s and 1960s,
combined with a complex social and political landscape, led
to the classification of several psychedelics as Schedule 1
drugs, which effectively shut down most research on these
substances and their potential clinical uses (Rucker, Iliff, &
Nutt, 2018).
The prohibition on psychedelic drugs was partially
justified by concerns regarding potential long-term negative
effects on mental health (Lee & Shlain, 1992). However,
subsequent studies failed to establish a link between lifetime
use of psychedelic drugs and increased rate of mental health
issues. Krebs and Johansen analyzed data from 130,152
randomly selected individuals, of which 21,967 reported at
least one experience with psychedelic drugs (Krebs &
Johansen, 2013). Their study failed to detect significant as-
sociations between psychedelic use and several markers of
impaired mental health, including serious psychological
distress, inpatient or outpatient mental health treatment,
and symptoms of nine psychiatric disorders. A follow-up
study by the same authors found the same results after
adjusting for sociodemographics, the use of other drugs, and
childhood depression (Johansen & Krebs, 2015). Converging
results have been published for controlled laboratory studies
(Nichols, 2016). Assessments by interdisciplinary panels of
experts consistently ranked psychedelics as some of the least
harmful recreational drugs, with safety profiles substantially
better than those of widely available and consumed drugs,
such as alcohol and tobacco (Nutt, King, & Phillips, 2010).
In recent years, the scientific and clinical interest in
psychedelics has increased considerably as a consequence of
a new wave of research demonstrating their potential in
neuroscience, psychiatry, and as adjuncts for psychotherapy
(Johnson & Griffiths, 2017; Kleber, 2016; Nichols & Hen-
dricks, 2020; Nutt & Carhart-Harris, 2020; Reiff et al., 2020).
One of the major promises of psychedelics as therapeutic
agents is their capacity to induce long-term psychological
and behavioral changes after a single session (Bouso, dos
Santos, Alcazar-Corcoles, & Hallak, 2018; Erritzoe et al.,
2018, 2019; Lebedev et al., 2016; MacLean, Johnson, &
Griffiths, 2011), which highlights their enormous potential
in the treatment of certain mood disorders and addictive
behaviors (Bogenschutz et al., 2015; Johnson, Garcia-
Romeu, Cosimano, & Griffiths, 2014; Johnson, Garcia-
Romeu, & Griffiths, 2017). Crucially, these effects appear to
be mediated by the nature of the induced psychedelic
experience, with reports of mystical-type experiences being
associated with better outcomes (Garcia-Romeu, Griffiths, &
Johnson, 2014; Griffiths et al., 2018; Johnson, Hendricks,
Barrett, & Griffiths, 2019). While these effects have been
shown for specific clinical populations, it could be hypoth-
esized that psychedelic use might lead to long-term mental
health benefits in healthy individuals. These benefits might
remain unnoticed until the individual is challenged by
adverse personal or social circumstances.
We investigated the relationship between lifetime psy-
chedelic use and multiple mental health indicators in the
context of the COVID-19 pandemic, an adverse event of
worldwide scope. COVID-19 is a contagious respiratory and
vascular disease caused by acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2). The rapid spread of COVID-19
during early 2020 precipitated drastic lockdown measures in
several countries, which in turn impacted negatively in the
mental health of the population (Pfefferbaum & North, 2020);
in particular, this study was conducted in Argentina, where
one of the longest lockdowns was declared between March
and November. Our first main objective was to determine
differences in mental health indicators (anxiety, positive and
negative affect, well-being, resilience) between individuals
who reported past psychedelic use, and those who declared
their past use of other psychoactive drugs. Our second
objective was to investigate the potential impact of lifetime
psychedelic use on personality traits, and how this potential
impact related to different mental health indicators.
MATERIALS AND METHODS
Survey
An anonymous Internet-based survey with two parts was
conducted between April 2020 and June 2020, i.e., between
one and three months after a severe lockdown was declared
in most of Argentina’s provinces. Recruitment advertise-
ments were shared via social media web pages (e.g., Face-
book, Instagram, and Twitter). The first part of the survey
was promoted as a questionnaire to understand the rela-
tionship between psychoactive drug use and mental health
during the COVID-19 pandemic, while the second part was
promoted as a questionnaire to determine personality traits.
The survey was presented in Spanish and each of its parts
took approximately 20 minutes to complete. The inclusion
criteria were providing online informed consent, being
Argentinian, older than 18 years and declaring male or fe-
male gender identity. Subjects received no compensation for
their participation.
Ethical approval
The procedure was included within a larger protocol for
online experimentation approved by the ethics committee of
Centro de Educacion Medica e Investigaciones Clınicas
Norberto Quirno. All participants gave their informed
consent before their participation in the present study.
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Questionnaires and scales
The full survey is available online (https://investigacion.
elgatoylacaja.com/concienciaysustancia/ and https://
investigacion.elgatoylacaja.com/personalidad/). The first
questionnaire collected sociodemographic variables (age,
gender, and nationality), variables related to past use of
psychoactive compounds (drugs that were consumed by the
user and their frequency of use – for a brief description of
the drugs included in the survey see the supplementary
material), and the STAI, PANAS, BIEPS, and RS scales. The
second part of the survey assessed personality via the BFI
questionnaire. Both questionnaires were independent from
each other.
State-Trait Anxiety Inventory (STAI): a commonly used
scale which measures state anxiety (which refers to a situa-
tional anxiety of a temporary nature) and trait anxiety
(which designates a stable trait linked to personal charac-
teristics) (Spielberger, Gorsuch, Lushene, & Inc, 1983). The
instrument comprises 40 items and is based on a 4-point
Likert scale, ranging from “Almost Never” to “Almost Al-
ways”.
Positive and Negative Affect Schedule (PANAS): a psy-
chometric scale that has been widely used to measure both
proposed dimensions of affect, positive and negative (Wat-
son, Clark, & Tellegen, 1988). The instrument consists of 20
affirmations based on a 5-point Likert scale, ranging from
“Not at all” to “Very much”.
Psychological Well-being Scale (BIEPS): a scale used to
measure eudaimonic well-being in adults (including di-
mensions of acceptance, perception of control, social ties,
and autonomy and projects) (Casullo & Brenlla, 2002). It
consists of 13 questions based on a 3-point Likert scale,
ranging from “Disagree” to “Agree”.
Resilience Scale (RS): a questionnaire aiming to evaluate
Resilience through the subscales of self-reliance, purpose
capacity and life meaning and cognitive avoidance (Wagnild
& Young, 1993). In this study a local adaptation was used
(Rodrıguez et al., 2009) which consists of 21 items based on
a 5-point Likert scale, ranging from “Fully agree” to “Fully
disagree”.
Big Five Inventory (BFI): an inventory assessing five
dimensions of personality: neuroticism, extraversion, open-
ness to experience, agreeableness, and conscientiousness
(Benet-Martinez & John, 1998). The BFI questionnaire
consists of 44 items based on a 5-point Likert scale, ranging
from “Fully disagree” to “Fully agree”.
Data processing and analysis
Data from the two questionnaires was merged according to a
unique identifier. Due to the scope of the ethics approval,
and because the local adaptation of psychometric scales is
limited to male and female Argentinian adults, only partic-
ipants older than 18 years old, residents of Argentina, and
with male or female gender identity were retained for sub-
sequent analysis.
Psychometric scales (i.e., STAI, PANAS, BIEPS, RS, BFI)
were scored using the subject’s answers, gender, and age to
obtain a value representing the results compared to values
previously obtained and tabulated for the local population
within the same gender and age group, according to the
procedure specified in each psychometric manual. Next, all
values were converted to a uniform scale between 0 and 10
(i.e., z-score) in order to facilitate comparison.
Data analysis was performed using Python 3.7.
Descriptive statistics (e.g., means, standard deviations, and
standard errors from the mean [SEM]) were used to char-
acterize the scale and subscale scores of the survey. Pearson’s
linear correlation coefficient was computed between all pairs
of scales and subscales to assess whether the different di-
mensions of our dataset were related as expected (e.g.,
positive correlations between the dimensions related to good
mental health). To reduce the dimensionality of the data and
thus the number of independent statistical tests, and to avoid
the issue of non-independent samples, we first conducted a
principal component analysis (PCA) of the data based on
computing the singular value decomposition of the centered
data matrix. The rows of the data matrix corresponded to
individual participants, and its columns contained binary
values indicating whether the participants reported lifetime
use of each drug, i.e., one drug per column. After grouping
the drug use variables into interpretable principal compo-
nents, we applied analysis of variance (ANOVA) followed by
Student’s t-tests to determine statistically significant differ-
ences between groups of users assigned to the different
principal components. Bonferroni correction for multiple
comparisons was applied whenever stated in the description
of the results. We note that PCA allowed us to group drugs
whose reported lifetime uses were highly correlated in a
data-driven way, thus avoiding the issue of non-independent
samples (i.e., subjects who consumed several drugs in the
past) without introducing ad-hoc groups.
RESULTS
During the data collection window (April 2020–June 2020),
11,365 individuals answered the first part of the survey
(demographics, drug use questionnaire, STAI, PANAS,
BIEPS, RS) and 157,101 answered the second part (BFI
questionnaire). Although both parts of the survey were
promoted in the same way, the second part achieved a much
higher level of dissemination in social media than the first
part, which led to the difference in the number of responses.
Of all the subjects, 10,722 answered both parts of the survey.
Of these, 5,104 were excluded as they failed to meet the
inclusion criteria presented in the “Materials and methods”
section. Thus, the final sample consisted of 5.618 partici-
pants who were 29.15 (±0.12) years old and 71.97% female.
32.43% of the total sample reported at least one use of a
psychedelic drug. All data is freely available at https://doi.
org/10.5281/zenodo.4324025.
The demographic information is summarized in Table 1.
Note that percentages in the first row of Table 1 do not add
to 100%, since reported uses of different drugs are not
exclusive (e.g., one participant could have reported past uses
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of different drugs). Similarly, Table 2 summarizes de-
mographic information for each PCA group and shows the
results of each psychometric subscale included in the survey.
Figure 1 summarizes the results of the BFI questionnaire
(panel A), and of the STAI, PANAS, BIEPS, and RS scales
(panel B). The latter were first transformed to Z-scores, so
that scores below/above zero indicate values that are below/
above the regional averages (these averages are the result of
the statistical analysis carried out when adapting a psycho-
metric scale in a given population). We observed that positive
affect (PA), well-being (W), and resilience (R) scores were
considerably below zero, which we can interpret as a potential
effect of the COVID-19 pandemic and its consequences.
Figure 1D and E shows the same information as in panels A
Table 1. The number of users, their gender identity and age corresponding to the subset of 5,618 participants who met the inclusion criteria
(i.e., Argentinian residents older than 18 years with male or female gender identity) classified by drug, by total number of drug users and
































Female (%) 52.70% 63.21% 62.86% 61.15% 75.00% 54.12% 42.86% 63.17% 76.19% 71.97%























Table 2. Survey results grouped by principal component scores. Psychometric scales and subscales results (STAI, PANAS, BIEPS, RS, BFI)
are presented as mean ± standard error
PCA components
Recreational Entheogen Prescribed Legal/Non-users
Demographics
% (n) 23.63 (1,328) 3.06 (172) 12.99 (730) 48.94 (2,750)
Sample percentage (%) 23.64 3.06 12.99 48.95
Female (%) 61.22 58.72 84.93 74.76
Male (%) 38.78 41.28 15.07 25.24
Age (mean ± sem) 27.21 ± 0.17 29.84 ± 0.61 32.59 ± 0.41 29.16 ± 0.18
Psych. assistance (%) 59.64 56.98 82.33 51.96
Hospitalization (%) 0.15 1.16 3.29 0.25
Medication (%) 0.53 0.00 24.25 0.25
STAI
State anxiety 24.62 ± 0.29 23.39 ± 0.85 29.08 ± 0.45 25.32 ± 0.22
Trait anxiety 25.25 ± 0.29 24.51 ± 0.85 29.74 ± 0.45 25.21 ± 0.22
PANAS
Negative affect 21.64 ± 0.20 21.23 ± 0.56 24.57 ± 0.30 21.43 ± 0.15
Positive affect 29.15 ± 0.21 30.90 ± 0.61 28.14 ± 0.29 29.33 ± 0.15
BIEPS
Acceptance 7.62 ± 0.04 7.72 ± 0.10 7.38 ± 0.06 7.64 ± 0.03
Autonomy 6.62 ± 0.04 6.90 ± 0.12 6.51 ± 0.06 6.60 ± 0.03
Social ties 8.18 ± 0.03 8.17 ± 0.09 7.88 ± 0.05 8.06 ± 0.02
Goals 10.02 ± 0.05 10.24 ± 0.13 9.73 ± 0.07 10.17 ± 0.03
Total well-being 32.45 ± 0.11 33.02 ± 0.30 31.50 ± 0.17 32.47 ± 0.08
RS
Self-reliance 57.58 ± 0.24 58.35 ± 0.68 55.65 ± 0.36 57.71 ± 0.18
Meaning 22.76 ± 0.13 23.18 ± 0.37 22.02 ± 0.19 23.48 ± 0.09
Cognitive avoidance 17.99 ± 0.12 17.78 ± 0.35 16.65 ± 0.18 18.22 ± 0.09
Total resilience 98.32 ± 0.40 99.31 ± 1.12 94.33 ± 0.61 99.41 ± 0.30
BFI
Extraversion 26.36 ± 0.16 26.42 ± 0.45 25.40 ± 0.23 25.57 ± 0.12
Agreeableness 32.88 ± 0.14 32.35 ± 0.36 32.61 ± 0.19 33.01 ± 0.10
Conscientiousness 29.49 ± 0.17 29.49 ± 0.51 30.64 ± 0.25 31.08 ± 0.13
Neuroticism 24.69 ± 0.18 24.41 ± 0.47 28.26 ± 0.23 25.16 ± 0.13
Openness 39.09 ± 0.17 40.64 ± 0.45 38.34 ± 0.24 37.70 ± 0.13
Alpha factor 77.69 ± 0.33 77.44 ± 0.93 74.98 ± 0.48 78.93 ± 0.24
Beta factor 65.44 ± 0.26 67.06 ± 0.70 63.74 ± 0.38 63.27 ± 0.19
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and B, but segmented according to the reported number of
psychedelic drug uses. The clearest trends can be observed in
panel D for the BFI scores, with the openness (O) and ex-
traversion (E) traits increasing as a function of reported uses,
and conscientiousness (C) showing the opposite behavior.
Figure 1C presents all pairwise correlations between subscales
with jRj > 0.3. The openness and agreeableness dimensions of
the BFI questionnaire were not correlated with any of the
other scales, while expected positive correlations between
state/trait anxiety (SA/TA), negative affect (NA), and
neuroticism were observed. Resilience and well-being were
positively correlated (and negatively correlated with state/trait
anxiety, negative affect and neuroticism), and also presented
positive correlations with positive affect, extroversion, and
conscientiousness. Alpha factor (AF)—which is conceptual-
ized as a combination of agreeableness, conscientiousness and
the inverse of neuroticism—showed positive correlations with
traits and states associated with healthy individuals (i.e., PA,
W, R, A, C) and negative correlations with states and traits
associated with a loss of functionality (i.e., SA, TA, NA, N),
whereas Beta factor (BF)—which is obtained as a combina-
tion of extraversion and openness—, showed only positive
correlations with traits and states associated with healthy
individuals (i.e., W, R, E, O).
We then performed a preliminary analysis by grouping all
scores from users who reported experience with each drug
and comparing those scores with the rest of the sample using
Student’s t-tests. Results are shown in Fig. 2. A double
dissociation effect is apparent: some psychedelic drugs
(mainly psilocybin mushrooms but also LSD and, to a lesser
degree, ayahuasca) were associated with lower scores of di-
mensions linked to mental health impairment (state/trait
anxiety, negative affect) and with higher scores of dimensions
linked to well-being and resilience (mainly positive affect,
autonomy, social ties, and well-being); conversely, other drugs
(including prescription drugs, caffeine, alcohol, tobacco, and
cannabis) were linked to higher scores of dimensions linked
to mental health impairment, and lower scores of dimensions
linked to well-being and resilience. Within this last group of
non-psychedelic drugs, MDMA showed different results
compared to the rest, being associated with higher scores of
the social ties dimension of the BIEPS.
We note that this analysis is preliminary since it does not
take into account the possibility of a single participant
declaring past experience with multiple drugs. To overcome
this limitation, we applied PCA to divide the sample into
groups of subjects with different drug use profiles. Each group
was created based on the scores along three principal com-
ponents: LSD, MDMA, psilocybin mushrooms, and dissocia-
tive drugs (“recreational”, i.e., drugs that are frequently
consumed in a recreational setting), DMT, ayahuasca, San
Pedro (Echinopsis pachanoi), bufo alvarius (Incilius alvarius),
and 5-MeO-DMT (“entheogen”, i.e., psychedelic compounds
that are frequently consumed in religious or ceremonial set-
tings), and antidepressants, antipsychotics, and sedatives
(“prescription”). The resulting components are shown in
Fig. 3A. To ensure that these groups were mutually exclusive,
participants with high scores in the “entheogen” and “recre-
ational” components were only included in the first, e.g., a user
with extensive lifetime use of LSD and ayahuasca would only
be included in the “entheogen” group. This reflects the
observation that most users with lifetime use of drugs in the
“entheogen” component also reported experiences with drugs
in the “recreational” component, but not vice versa. Subjects
presenting high scores for drugs in the “prescription”
component were included in the corresponding group,
regardless of their scores in the other two components. Finally,
we created a group for participants who only declared past
experiences with legal drugs, such as caffeine, alcohol and
tobacco (“legal/non-users”). 11.36% of the sample did not
clearly fit in any group based on the PCA scores, and hence
was discarded from subsequent analysis.
Fig. 1. Summary of the BFI questionnaire (panel A), the STAI, PANAS, BIEPS and RS scales (panel B), both as a function of the reported
number of psychedelic drug uses (panels D and E), and all pairwise correlations between subscales with jRj > 0.3. Abbreviations: O
(Openness), C (Conscientiousness), E (Extraversion), A (Agreeability), N (Neuroticism), SA (State anxiety), TA (Trait anxiety), NA
(Negative affect), PA (Positive affect), W (Well-being), R (Resilience), AF (Alpha factor), BF (Beta factor)
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Fig. 3. Principal components. A) Word clouds representing the drugs included in the different groups, with word size indicative of the
weight of the drug in the corresponding principal component. B) Radar plots showing BFI scores (left), psychometric scale scores (middle)
and their subscales (right) for participants belonging to each group, plus a group of participants who only declared past use of legal drugs
(e.g., caffeine, alcohol, tobacco). Abbreviations: O (Openness), C (Conscientiousness), E (Extraversion), A (Agreeability), N (Neuroticism),
SA (State anxiety), TA (Trait anxiety), NA (Negative affect), PA (Positive affect), W (Well-being), R (Resilience), ACC (Acceptance), AUT
(Autonomy), ST (Social ties), G (Goals), SR (Self-reliance), M (Meaning), CA (Cognitive avoidance)
Fig. 2. Preliminary analysis comparing questionnaire scores corresponding to individual drugs vs. all others. Each entry in the matrix
corresponds to the effect size (Cohen's d) for the comparison of the score (columns) for the drug (rows) vs. all other drugs grouped together.
Only significant entries are shown (P < 0.05, Bonferroni corrected for 16 3 13 5 208 comparisons). Abbreviations: SA (State anxiety), TA
(Trait anxiety), NA (Negative affect), PA (Positive affect), Acc (Acceptance), Aut (Autonomy), ST (Social ties), G (Goals), W (Well-being),
SR (Self-reliance), M (Meaning), CA (Cognitive avoidance), R (Resilience)
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We first applied an ANOVA test to find a significant
effect (P < 0.05, Bonferroni corrected for 4 comparisons) of
user group in all BFI scores and psychometric scales except
for the agreeableness personality trait (P 5 0.121).
We applied pairwise Student’s t-test to determine
whether the variables plotted in Fig. 3B presented significant
differences between the four groups of participants. The
results of this analysis are shown in Fig. 4 (state/trait anxiety,
BFI, PANAS, BIEPS, and RS) and Fig. 5 (alpha and beta
factors). Figure 5C also presents the second order person-
ality factors alpha and beta as a function of the reported
number of lifetime psychedelic experiences.
The “recreational” group presented higher extraversion
and lower conscientiousness scores than the group of non-
users, while both “recreational” and “entheogens” resulted in
increased openness scores, as expected from previous studies.
Also as expected, neuroticism was increased in the “pre-
scription” group relative to all others. No differences were
found for the agreeableness personality dimension. Subjects in
the “entheogen” group presented higher openness than those
in the “recreational” group (Fig. 4A). All measures positively
associated with mental health were significantly lower in the
“prescription” group; also, we observed higher positive affect
in the “entheogen” group compared to all others (Fig. 4B).
Finally, the alpha factor was lower for the “prescription”
group compared to all others (Fig. 5A), and the beta factor
was higher for the “recreational” and “entheogen” groups
compared to the other two groups (Fig. 5B). Also, the beta
factor increased with the reported number of lifetime psy-
chedelic experiences (Fig. 5C).
Fig. 4. Comparison of psychometric scales and subscales between groups of participants. A) Comparison of BFI dimensions. B) Comparison
of trait/state anxiety, positive and negative affect, well-being and resilience. *P < 0.05 (Bonferroni corrected for 4 comparisons), **P < 0.01,
***P < 0.05
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DISCUSSION
The current study investigated the relationship between
lifetime use of psychoactive drugs and reported levels of
anxiety, positive and negative affect, well-being, resilience,
and personality traits. We focused our analysis on the pos-
sibility that psychedelic drugs could confer sustained bene-
fits, which are manifested as better mental health indicators
during the ongoing COVID-19 pandemic.
Concerning the general mental health status of the
sample, after scoring positive and negative scales and
transforming them to z-scores we compared the results to
the regional average and observed reduced values, particu-
larly in resilience (2.74), but also in well-being (0.74) and
PANAS positive affect (0.54), and higher values in STAI
state anxiety (0.3), STAI trait anxiety (0.28), and PANAS
negative affect (0.06) (Fig. 4, panel B), in all cases compared
to the normative values corresponding to the age- and
gender-adjusted regional average. We expected an effect on
mental health indicators as a consequence of the social
isolation and uncertainty associated with the COVID-19
outbreak. This result is in line with preliminary reports
showing serious consequences in the mental health of the
general population during the pandemic (Brooks et al., 2020;
Gallagher et al., 2020; Pfefferbaum & North, 2020; Zacher &
Rudolph, 2020).
We observe that our results successfully replicated
known results concerning the relationship between person-
ality traits and different mental health indicators (Widiger &
Trull, 1992; Widiger & Costa, 1994, Mineka, Watson, &
Clark, 1998; Kotov, Gamez, Schmidt, & Watson, 2010; Beck,
Davis, & Freeman, 2015). Figure 1C confirms the positive
correlation between BIEPS, RS, and PANAS positive affect
scores, and negative correlations between STAI trait and
state, and PANAS negative affect (Hu, Zhang, & Wang,
2015). Concerning personality traits, neuroticism correlated
both with temporary psychological states (i.e., negative
affect, state anxiety) and more stable personality character-
istics (i.e., trait anxiety), confirming a significant association
between this trait and negative emotion (Costa and McCrae,
1977, 1980; John, Naumann, & Soto, 2008). Higher order
traits also behaved as expected, beta factor being correlated
with the well-being and resilience scores, and alpha factor
behaving opposite to the neuroticism trait, i.e., exhibiting
similar correlations of the opposite sign (B€ackstr€om, 2007;
Kardum & Hudek-Knezevic, 2012).
We investigated the relationship between self-reported
drug use and the psychometric questionnaire scores by first
applying principal component analysis to group subjects
according to their experiences with psychoactive drugs.
These groups reflected how the use of drugs was clustered in
our sample: the first component included mainstream psy-
chedelic, entactogen, and dissociative drugs, most of which
are consumed in recreational contexts; the second group
only included serotonergic psychedelics that are commonly
consumed in religious or ceremonial context; the final group
included prescription psychoactive drugs such as antide-
pressants, antipsychotics and sedatives. This classification
was useful to highlight the specific effects of certain psy-
chedelic drugs, which likely transcend their pharmacological
action and emerge as a consequence of interactions with
contextual factors (i.e., set and setting) (Carhart-Harris &
Fig. 5. Comparison of second order personality traits between groups of participants. A) Comparison of alpha factor scores. B) Comparison
of beta factor scores. C) Alpha and beta factor vs. reported number of lifetime psychedelic experiences. *P < 0.05 (Bonferroni corrected for 4
comparisons), **P < 0.01, ***P < 0.05
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Goodwin, 2017; Kazdin, 2007; Mulder, Murray, & Ruck-
lidge, 2017).
We confirmed that experience with psychedelic drugs
was associated with changes in personality traits indexing
the experience of novelty (Bouso et al., 2018; Erritzoe et al.,
2018, 2019; Lebedev et al., 2016; MacLean et al., 2011).
Openness refers to active curiosity in the intellectual
domain, while extraversion, represents openness behavioral
counterpart but oriented to the material world, involving an
active type of curiosity that includes (but is not limited to)
social interactions (DeYoung, Peterson, & Higgins, 2002).
Both openness and extraversion are functional characteris-
tics, since a person who faces the environment in a positive
way is more likely to obtain reinforcement from the inter-
action and thus adapt his or her behavior accordingly,
suggesting a link between these traits and serotonergic and
dopaminergic circuits (Ashby & Isen, 1999; Depue &
Collins, 1999; DeYoung et al., 2002). As shown in Fig. 1D,
the reported number of psychedelic drug uses was positively
correlated with openness and extraversion; furthermore,
lifetime use of psychedelic were linked to significant in-
creases in these traits (with the exception of the extraversion
trait for the “entheogen” group). Although these results are
particularly interesting, due to the nature of our study we
cannot confirm whether this increment was caused by life-
time use of psychedelic drugs, or due to different pre-
existing personality traits psychedelic drug users.
Concerning second order personality traits, alpha and
beta factors presented significant increases in the groups of
psychedelic users, and the reported number of psychedelic
uses correlated with both traits. The alpha factor is obtained
as a combination of agreeableness, conscientiousness and
the inverse of neuroticism, and has been interpreted as a
measure of social desirable traits (B€ackstr€om, 2007; Kardum
& Hudek-Knezevic, 2012). This factor has significantly
increased in the “recreational” group but not in the
“entheogen” group. The beta factor is obtained as a com-
bination of extraversion and openness and has been inter-
preted as a striving for self-assertion and self-expansion
(B€ackstr€om, 2007; Kardum & Hudek-Knezevic, 2012). This
factor was significantly increased in both the “recreational”
and “entheogen” group, and also correlated positively with
the reported number of psychedelic drug uses. Alternatively,
the alpha and beta factors have been interpreted in terms of
“stability” and “plasticity”, respectively (DeYoung et al.,
2002; Digman, 1997). The positive association between
lifetime use of psychedelics and these personality traits
suggests enhanced resilience and well-being in the light of
challenging situations (Fig. 1C).
Certain considerations can be drawn in regards to the
link between psychedelics and changes in personality traits.
First, since some of these changes could be related to 5-HT2A
receptor expression and activation (Kalbitzer et al., 2009), it
is hypothesized that a pharmacological interaction occurring
in a sustained way could modify genetic expression and thus
promote stable modifications in the personality of the users
and therefore also in their behavioral patterns (Bouso et al.,
2018). In this case, a causal link could exist between the
changes in personality trait and the reported number of psy-
chedelic drug uses (Fig. 5C). Second, this could also offer
psychotherapeutic potential by external modulation of per-
sonality traits. This can be considered both an end by itself
(e.g., in the case of certain disorders), or an intermediate
objective if the therapeutic goal is to make the patient more
flexible to work on psychopathological aspects underlying their
personality style (e.g., mood disorders like depression, caused
by personality disorders like avoidant personality disorder).
Additionally, all the personality traits evaluated in this
study (i.e., extraversion, agreableness, conscientiousness,
neuroticism, openness), and their second order factors (i.e.,
alpha and beta) are psychological representations whose
utility is to model the most stable and durable cognitive style
of individuals. As a stable factor, personality bears a large part
of the variance of the temporal states of mind (e.g., the clinical
association between psychopathological conditions and the
neuroticism trait). Likewise, these temporary states are caused
by the cognitive evaluation resulting from the interaction with
the environment, and influence secondary constructions that
involve self-evaluation (i.e., well-being and resilience). It is
therefore appropriate to propose a logical order in which the
variables of this study are linked: the most stable factors
(personality traits and anxiety as a trait) influence the
cognitive style that is responsible for interpreting and pro-
cessing reality. In turn, what is interpreted affects emotions,
which can be considered as temporary cognitive states (anx-
iety, positive affect, negative affect). The sustained summation
of these states makes up, among other things, the self-
perceived processes of well-being and resilience.
We must clarify certain limitations arising from meth-
odology. First, it is not possible to corroborate the infor-
mation given by the participants, especially concerning the
identity and dose of the psychoactive drugs they consumed.
Second, it is possible that variables outside the scope of our
survey are influencing the results we obtained. Concerning
this limitation, our principal component analysis aimed to
alleviate the effect of confounds caused by poly-drug use by
dividing the sample into disjoint groups depending on their
principal component values. Finally, it was not possible to
draw causal inferences due to our study design.
In summary, we performed a survey to investigate the
relationship between mental health, personality and past
drug use during the COVID-19 pandemic. Our results do
not suggest an association between past psychedelic use and
impaired mental health indicators; on the contrary, we
found evidence supporting a more resilient and stable per-
sonality structure in those subjects who reported repeated
use of certain psychedelic compounds. This study adds to
the existing literature on the relationship between mental
health and lifetime psychedelic use by investigating self-re-
ported measures of well-being during a highly challenging
situation known to cause adverse psychological responses.
Future studies should investigate with more detail whether
our results can be attributed to the long-term changes
induced by psychedelics, and how these changes relate to the
available evidence concerning the potential use of psyche-
delics in the treatment of psychiatric disorders.
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